Participants will take both tablets each day for several months while attending regular clinic visits for blood draws and bone‑marrow checks. A molecular response 2, abbreviated MR2, means the level of the genetic marker BCR::ABL1 in the blood is 1 % or lower, indicating a low amount of disease. A complete cytogenetic response, meaning no cancer‑related chromosome changes are seen in a sample of bone marrow cells, will also be assessed. Safety will be monitored by recording any adverse events, which are side effects that may range from mild to serious. The study will conclude after the final safety and effectiveness evaluations are completed.

The study follows people who have already completed an earlier asciminib study and are considered by the doctor to still benefit from treatment. Treatment is continued over time, and regular study visits are planned so that health and any side effects can be watched. The study looks at possible adverse events, which are unwanted health problems that happen during treatment, and serious adverse events, which are more severe health problems. In some parts of the study, other tyrosine kinase inhibitors that may have been used in earlier studies include nilotinib, dasatinib, imatinib, and bosutinib.

The study is designed to provide continued access to the same study treatment received before while long-term safety is followed over time.

Participants will take asciminib during the study and will have regular study visits over time. The study will follow how the disease responds, how long the response lasts, and whether the treatment causes side effects. Growth and development will also be checked, including height or length, weight, bone growth, and puberty changes. The study is planned as a single-group trial, so all participants receive the same study treatment.

The purpose of the study is to evaluate how well these treatments work in achieving a deep molecular response, which means a significant reduction in cancer cells, in patients who are newly diagnosed with this type of leukemia. Participants will receive treatment over a period of time, and their response to the medication will be monitored regularly. The study aims to understand how quickly and effectively the treatments can reduce the presence of cancer cells in the blood.

Throughout the study, researchers will also observe the long-term outcomes for patients, including their overall survival and the possibility of maintaining remission without ongoing treatment. The study will help determine the best approach for using Asciminib and Tasigna in treating patients with Chronic Myeloid Leukemia who have the BCR-ABL1 marker. This research is important for improving treatment strategies and outcomes for individuals with this specific type of leukemia.

The study is divided into two parts. In the first part, participants will be randomly assigned to receive either Olverembatinib or Bosutinib to compare their effects. In the second part, the focus will be on patients with a specific genetic change in their cancer cells, known as the T315I mutation, to evaluate how well Olverembatinib works for them. The study will last for up to 48 weeks, with regular check-ups to monitor the response to the treatment and any side effects. Participants will be closely observed to ensure their safety and to gather information on how the treatments affect their health and quality of life.

This trial aims to provide valuable insights into the potential benefits of Olverembatinib for patients with chronic phase CML, especially those who have not responded well to other treatments. The findings could help improve treatment options for this type of leukemia, offering hope for better management of the disease.

Participants in the study will receive either Bosutinib alone or in combination with Ropeginterferon Alfa-2B. The study will monitor the participants over a period to see how well the treatments work in achieving a deep molecular response, which means a significant reduction in cancer cells. The goal is to increase the number of patients who can eventually stop treatment and remain in remission, which is when the disease is not active.

The study will follow participants for several months, with regular check-ups to assess their response to the treatment and any side effects they may experience. The researchers aim to understand how these treatments can help manage Chronic Myeloid Leukemia and improve the quality of life for those affected by this condition.

The purpose of this research is to determine how long patients survive when treated with this drug combination over a two-year period. The treatment plan involves taking ponatinib tablets daily and receiving azacitidine injections for 7 days during each treatment cycle. The maximum daily dose of ponatinib is 45 mg, while azacitidine is given at 75 mg per square meter of body surface.

During the study, patients will be monitored for their response to treatment and any side effects they may experience. Doctors will regularly check blood samples and perform other medical tests to evaluate how well the treatment is working. The study will track various measures of treatment success, including changes in blood cell counts and the presence of cancer cells.

The purpose of the study is to determine if low-dose DOACs are more effective than low-dose Aspirin in preventing blood clots in high-risk patients with these blood disorders. Participants in the study will be randomly assigned to receive either Apixaban, Rivaroxaban, or Aspirin. The study will monitor the time it takes for any blood clotting events to occur, as well as any significant bleeding events. The study will also look at other health outcomes, such as overall survival and quality of life, over a period of 24 months.

Throughout the study, participants will take their assigned medication orally, and their health will be closely monitored by the research team. The study will help to better understand which medication is more effective in preventing complications related to blood clots in patients with these specific blood disorders. The findings could lead to improved treatment options for individuals with these conditions.

The purpose of the study is to compare two different strategies for stopping the use of TKIs in patients with CML. The study will explore how these strategies affect the likelihood of successfully discontinuing the medication while monitoring the impact on the immune system. Participants will be randomly assigned to one of the two strategies and will be followed for a period of time to observe the outcomes. Some participants may receive a placebo as part of the study.

Throughout the study, participants will be monitored for any changes in their condition and any side effects they may experience. The study aims to gather information on the proportion of patients who can maintain treatment-free remission, which means staying in remission without the need for ongoing medication. The study will also collect data on the quality of life and any adverse events that occur. The estimated end date for the study is June 2029.

The main purpose is to determine if patients can safely stop their treatment and remain in remission (when the disease is under control). The study involves two attempts at treatment-free periods. In the first attempt, patients who have been taking nilotinib will try stopping their medication. If this is not successful, patients will receive a combination of nilotinib and asciminib before attempting a second treatment-free period.

Throughout the study, patients will be closely monitored through regular blood tests to measure the levels of disease markers. The total duration of the study is approximately 144 weeks, during which patients will receive different combinations of medications or attempt periods without treatment, depending on how their disease responds.

The purpose of this research is to find out if adding these new treatments to existing therapy can help more patients achieve a deeper level of response to treatment. The study will last for 12 months, during which patients will receive either Actos tablets up to 45 mg daily or avelumab infusions at doses calculated based on body weight, in addition to their regular cancer medication.

Throughout the study, doctors will monitor how well the treatment is working by measuring the levels of cancer markers in the blood. They will also track any side effects that patients may experience. The treatment schedule and doses will be determined by the study doctors based on each patient’s individual needs and response to the medication.

Participants in this study will have been treated with dasatinib for at least two years and must have shown a significant reduction in disease markers for at least one year. The study will observe patients over a period to see if they can maintain remission without the medication. The trial will also look at various factors that might influence the success of stopping the medication, such as biological markers and previous treatment history.

The study will monitor the proportion of patients who maintain remission at six and twelve months after stopping the medication again. It will also track any side effects that occur when the medication is stopped and any factors that might predict the success of stopping the medication. The trial aims to provide insights into the possibility of living without continuous medication for those with Chronic Myeloid Leukemia.

The purpose of the study is to determine if the combination of asciminib and imatinib is more effective than the other treatment options. Participants will be randomly assigned to one of the treatment groups and will take the medications orally, which means by mouth, in the form of film-coated tablets or capsules. The study will last for a period of up to 96 weeks, during which the participants’ response to the treatment will be monitored.

Throughout the study, the main focus will be on the rate of achieving a deep molecular response, known as MR4.5, at 48 weeks. This response indicates a very low level of cancer cells in the blood. The study will also look at the safety of the treatments, any side effects, and how the medications are processed in the body. Participants will have regular check-ups and tests to monitor their health and the effectiveness of the treatment.

The purpose of this research is to evaluate how patients respond when their medication dose is reduced. The study will monitor patients who have shown a good response to their current treatment and investigate if maintaining disease control is possible with lower doses of these medications.

During the study, participants will continue taking their prescribed medication but at reduced doses. The treatment period will last for 12 months, during which doctors will regularly monitor the patient’s response to the adjusted medication doses. All medications will be taken by mouth. The maximum daily doses vary depending on the specific medication: imatinib (800 mg), ponatinib (45 mg), bosutinib (500 mg), nilotinib (400 mg), or dasatinib (140 mg).

The purpose of the study is to evaluate how well Ponatinib works when given in different doses: 45 mg, 30 mg, and 15 mg daily. Participants will take the medication in the form of film-coated tablets, which are taken orally. The study will monitor the participants over a period to see how their condition responds to the treatment. The goal is to see if the medication can reduce the levels of a specific protein associated with CML, known as BCR-ABL1, to a very low level within 12 months. This protein is a marker used to measure the presence of cancer cells in the body.

Throughout the study, the safety of Ponatinib will also be assessed by observing any side effects or adverse reactions that participants may experience. The trial aims to provide valuable information on the best dosage of Ponatinib for treating patients with resistant CML, helping to improve treatment options for those affected by this condition.

The treatment being tested is a medication called asciminib (also known as Scemblix or ABL001). This medication comes in the form of film-coated tablets that are taken by mouth. The study aims to determine how well patients respond to asciminib after 12 months of treatment.

During this open-label study, all participants will receive asciminib tablets. The treatment may continue for up to 48 months, with regular check-ups to monitor how well the medication is working and to watch for any side effects. The amount of medication can be adjusted based on how each patient responds to the treatment.

The study is divided into two phases. In the first phase, the goal is to find the best dose of Ponatinib for children with advanced blood cancers or solid tumors. In the second phase, the study will look at how well Ponatinib works in children with a specific type of leukemia called Chronic Myeloid Leukemia (CML) and other selected cancers. Participants will take Ponatinib orally, which means they will swallow it in the form of a tablet or capsule. The study will monitor the participants’ health and any side effects they may experience while taking the medication.

Throughout the study, researchers will assess the participants’ response to the treatment by using various medical tests and imaging techniques like MRI or CT scans. The study aims to provide valuable information on the potential benefits and risks of using Ponatinib in treating these challenging cancers in children. The study is expected to continue until 2025, allowing researchers to gather comprehensive data on the long-term effects of the treatment.

The purpose of the study is to find the best dose of Bosutinib for children with CML and to understand how the drug behaves in their bodies. The study will also look at the safety and side effects of the medication. Participants will take the medication in the form of capsules or film-coated tablets, which are taken by mouth. The study will be conducted in two phases. In the first phase, different doses of the medication will be tested to find the most suitable one. In the second phase, the study will focus on how the medication is processed in the body and its overall safety.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the medication. The study aims to gather information that could help improve treatment options for children with Chronic Myeloid Leukemia. Participants will be closely monitored for any side effects or changes in their condition, and the information collected will contribute to understanding the effectiveness and safety of Bosutinib in treating this type of leukemia in children.

The purpose of the study is to see how well Asciminib Hydrochloride works compared to the other TKIs in helping patients achieve a significant reduction in cancer cells, known as a Major Molecular Response, by the 48th week of treatment. Participants in the study will be randomly assigned to receive either Asciminib Hydrochloride or one of the other TKIs. The study will last for a period of up to 72 weeks, during which participants will take the medication orally, meaning by mouth, in the form of tablets or capsules.

Throughout the study, participants will have regular check-ups to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on the best treatment options for patients newly diagnosed with Chronic Myeloid Leukemia in the chronic phase. This research could help improve treatment strategies and outcomes for patients with this type of leukemia.

The purpose of the study is to determine the appropriate dose and safety of Asciminib in children with this type of leukemia. The study will involve giving the medication to pediatric patients and monitoring how their bodies process the drug. This will help researchers understand how the drug behaves in children compared to adults. The study will also look at the safety of the medication by observing any side effects that may occur during the treatment period.

Participants in the study will take Asciminib orally, and the study will track their response to the medication over time. The researchers will collect information on how well the drug is tolerated and its effects on the leukemia. The study aims to find a dose that provides similar drug exposure in children as seen in adults, ensuring the treatment is both effective and safe for younger patients. The study will also gather feedback on how acceptable and palatable the medication is for the children taking it.

The purpose of the study is to see how well patients with CML-CP respond to Asciminib after they have already been treated with at least two other medications called tyrosine kinase inhibitors (TKIs). These TKIs include drugs like imatinib, nilotinib, dasatinib, bosutinib, radotinib, or ponatinib. The study will look at how many patients achieve a specific type of response called a molecular response at different times, such as at 48 weeks. The study will also monitor the safety of the treatment by checking for any side effects and changes in health markers.

Participants in the study will take the medication for a period of up to 144 weeks. During this time, they will have regular check-ups to monitor their health and the effectiveness of the treatment. The study aims to provide more information on how well Asciminib works for patients with CML-CP who have not had success with other treatments.

Participants in the study will be randomly assigned to receive either Asciminib Hydrochloride or Nilotinib. The study will monitor how long patients can continue the treatment without stopping due to side effects. The trial will also look at how well the medications work in controlling the disease over time. Patients will be regularly assessed to track their response to the treatment and any side effects they may experience.

The study aims to provide valuable information about the safety and effectiveness of these treatments for people newly diagnosed with Chronic Myelogenous Leukemia in the chronic phase. The trial is expected to run for several years, allowing researchers to gather comprehensive data on the long-term outcomes of using these medications. Participants will receive regular check-ups and support throughout the study to ensure their well-being and to gather necessary information for the research.

The purpose of this research is to determine if starting treatment with Nilotinib is more effective than starting with Imatinib and then switching to Nilotinib if the initial response is not optimal. The study will examine how well these treatments work in helping patients achieve and maintain a treatment-free period where their disease remains under control without ongoing medication.

During the study, which lasts up to 48 months, patients will receive either Nilotinib (up to 600 mg daily) or Imatinib (up to 400 mg daily). Doctors will monitor the amount of cancer cells in the blood throughout the treatment period to determine how well the medications are working. The study will track how many patients can successfully stop treatment while maintaining control of their disease.

Participants in the study will take Ponatinib orally, which means they will swallow the tablets. The study will observe how well patients maintain their response to the treatment over a period of time. The study will also monitor any new or worsening side effects that may occur during the treatment. The goal is to see how many patients can maintain their response without the need for continuous treatment.

The study will last for a set period, during which patients will be regularly monitored to assess their health and response to the treatment. This includes checking for any adverse events, such as blood-related issues or digestive problems, and ensuring that the disease does not progress. The study aims to provide insights into the potential for patients to live without ongoing treatment while maintaining their health.

The purpose of this research is to evaluate how well the combination of asciminib with other medications that target the same cancer-causing proteins works in achieving a deep reduction in cancer cells in patients who have not received previous treatment for their disease. The treatment period lasts for 21 days, and patients will be monitored to assess how their body responds to the medication.

The study involves regular medical check-ups to monitor the patient’s health status and response to treatment. Blood tests will be performed to measure the levels of cancer cells and to check how well the patient’s organs are functioning. The medication being studied is designed to specifically target the genetic change that causes this type of leukemia, known as the Philadelphia chromosome.

Participants in the study will take Pioglitazone and TKIs together, and their health will be monitored over a period of time. The study will look at how well patients do without losing a specific response to treatment, known as MMR (Major Molecular Response), over a 12-month period after stopping the combination of Pioglitazone and TKIs. This will involve regular blood tests to check for the presence of a specific marker called BCR-ABL1, which is associated with CML. The study will also keep track of any side effects that participants might experience while taking the combination of medications.

The trial aims to provide valuable information on whether the combination of Pioglitazone and TKIs can help patients maintain their health after stopping TKIs, potentially leading to new treatment strategies for those with CML. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

The purpose of this research is to evaluate how well venetoclax works in targeting remaining cancer cells in patients who stop their TKI therapy. The medication venetoclax, also known as ABT-199, is taken by mouth once daily at a dose of 400 mg. The treatment period lasts for up to 12 months.

During the study, researchers will monitor how the medication affects the remaining cancer cells in the bone marrow. The study focuses on patients whose cancer has responded well to previous treatment, showing very low levels of cancer cells in their body. This is measured through special laboratory tests that look for specific genetic markers associated with CML.